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Abstract
Background Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with 177Lu-labeled PSMA ligands
has achieved remarkable results in advanced disease stages of metastatic castration-resistant prostate cancer (mCRPC). However,
not all patients benefit from this therapy. Different treatment responses could be explained by tumor heterogeneity triggered by
progression and the number of prior treatments. PSMA-negative lesions can be missed on PSMA ligand PET/CT, which
subsequently results in an underestimation of tumor burden. Conversely, high FDG uptake may also be an indicator of tumor
aggressiveness and thus a poor prognostic marker for response to RLT and overall survival (OS). The aim of this analysis was to
investigate the prognostic value of combined PSMA ligand PET/CT and [18F]fluorodeoxyglucose (FDG) PET/CT for outcome
prediction in patients undergoing RLT.
Materials and methods This bicentric analysis included 54 patients with mCRPC who underwent both FDG and PSMA ligand
PET/CT imaging before RLT. In all patients, the pattern of PSMA ligand and FDG uptake was visually assessed. Patients with at
least one FDG-positive, but PSMA-negative (FDG+/PSMA−) lesions were compared to patients without any FDG+/PSMA−
lesions. A log-rank analysis was used to assess the difference in OS between subgroups.
Results Median OS was 11 ± 1.8 months (95% CI 7.4–14.6). A significantly lower OS (p < 0.001) was found in patients with at
least one FDG+/PSMA− lesion at baseline PET/CTs (n = 18) with a medianOS of 6.0 ± 0.5 months (95%CI: 5.0–7.0 months). In
comparison, patients without any FDG+/PSMA− lesions (n = 36) had a median OS of 16.0 ± 2.5 months (95% CI: 11.2–
20.8 months).
Conclusion FDG+/PSMA− lesions are a negative predictor of overall survival in patients with mCRPC undergoing RLT.
However, it remains to be determined if patients with FDG+/PSMA− lesions should be excluded from PSMA RLT.
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Introduction
In advanced prostate cancer, tumor progression under androgen
deprivation marks the transition from a hormone-sensitive to a
castration-resistant stage of disease [1]. In metastatic castration-
resistant prostate cancer (mCRPC), several classes of medical
treatment have successfully prolonged survival, including next-
generation androgen receptor signaling inhibitors such as
abiraterone and enzalutamide [2, 3], or chemotherapy with do-
cetaxel and cabazitaxel [4] [5] [6]. Additionally, prostate-specific
membrane antigen- (PSMA) targeted radioligand therapy (RLT)
with [177Lu]-labeled PSMA-ligands has achieved remarkable
results in advanced disease stages [7]. The most important selec-
tion criterion for RLT is a high expression of PSMAof the tumor
as assessed by adequate tracer uptake on PSMA ligand PET/CT
[8]. Nevertheless, the patient group scheduled for PSMA-
directed RLT is most likely heterogeneous both in terms of prior
treatment as well as in terms of tumor biology. Parameters which
may help in predicting and optimizing response rates to RLT are
under investigation, such as additional assessment of tracer up-
take on [18F]fluorodeoxyglucose (FDG) PET/CT that appears to
be useful for the detection of more aggressive disease [9, 10]. In
line with this, the semiquantitative measurement of FDG uptake
at baseline FDG PET/CT appears to deliver independent prog-
nostic information on overall survival (OS) in mCRPC [11]. In
patients undergoing RLT with [177Lu]Lu-PSMA 617, a high
baseline FDG uptake was associated with higher Gleason scores
and poorer progression-free survival [12]. As tumor PSMA ex-
pression can decrease or get lost during several lines of treatment,
additional FDG PET/CT scanning may play an important role in
the detection of such lesions [13] [14]. Lesions showing in-
creased FDG-uptake but no relevant uptake on PSMA ligand
PET (FDG+/PSMA−) have been used as an exclusion criterion
prior to PSMARLT in a recent single-centre, single-arm phase 2
study with [177Lu]Lu-PSMA 617 therapy in patients with
mCRPC (LuPSMA Trial) [14]. Whereas encouraging results
could be shown for patients receiving RLT [14, 15], the subjects
excluded from the trial due to FDG+/PSMA− lesions had a very
poor OS under standard of care [16].
The aim of this bi-centric retrospective study was to eval-
uate the rate of FDG+/PSMA− lesions on PSMA ligand and
FDG PET/CT in patients undergoing RLT and their prognos-
tic implications. Therefore, dual FDG and PSMA ligand PET/




Searching the databases of the University Hospital Würzburg
for the period between December 2018 and February 2020
and that of the University Hospital Freiburg for the period
between August 2018 and December 2019, all consecutive
patients who underwent at least one cycle of RLT as systemic
treatment for mCRPC were identified. PSMA ligand PET/CT
was performed to assess eligibility for PSM-directed RLT. In
case of adequate PSMA expression, the patients routinely
underwent a subsequent FDG PET/CT scan to assess the pres-
ence of PSMA-negative metastases. In case of PSMA-
negative metastases, PSMA RLT was only offered if the ma-
jority of metastases was PSMA-positive, and if PSMA RLT
was the last therapeutic option.
Time intervals between PET/CT scans and first administra-
tion of RLT were as follows: PSMA ligand PET/CT and FDG
PET/CT 24.9 ± 18.0 days (range: 1–68); PSMA ligand PET/
CT and first cycle of RLT 35.6 ± 20.9 days (range: 2–85).
The study was approved by the local ethics committees
(Freiburg: protocol no. 251/17; Würzburg: protocol no.
20190815 01).
Imaging and treatment protocol
Whole-body PET scans were acquired using a PET/CT scanner
with either full-dose contrast-enhanced diagnostic CT (PSMA
ligand) or low-dose CT (FDG) for attenuation correction and
anatomical co-registration. Both PET/CT studies were per-
formed on two separate days. A detailed description of the im-
aging protocols can be found in the supplementary material.
Standardized institutional protocols for RLT work-up were ap-
plied. In-house labeling was carried out for [177Lu]-labeled
PSMA ligands ([177Lu]Lu-PSMA I&T (Würzburg), and
[177Lu]Lu-PSMA 617 (Freiburg), which are considered compa-
rable in their efficacy [8]. The standard PSMA RLT protocol
consisted of infusion of 6.0 GBq of the radioligand every 6–
8 weeks with up to 4 cycles depending on response to treatment.
Image analysis
PET/CT images were retrospectively analyzed using commer-
cial software packages (Würzburg: Syngo.via; VB30A,
Siemens Healthcare, Erlangen, Germany; Freiburg: IMPAX
EE; Agfa Health Care, Bonn, Germany). All lesions with
non-physiological, higher uptake of the PSMA ligand or
FDG than the physiological background were rated as PSMA
− or FDG-positive, respectively. No size threshold was defined
for positive lesions. Images were visually evaluated indepen-
dently by two nuclear medicine specialists with at least 1-year
experience in PET/CT reading using two categories: presence
of one or more discordant lesions (FDG-positive but PSMA-
negative) or absence of discordant FDG+/PSMA− lesions.
These visual categories were established and validated in
Freiburg by two readers (KM and CG) using the first 10 in-
cluded patients. Interobserver agreement in the training phase
was substantial, as indicated by Cohens κ = 0.78, based on
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Landis and Koch criteria [17]. Figure 1 gives examples of the
categories. Furthermore, the number of discordant lesions was
noted (1 lesion, ≤ 3 lesions, or ≥ 4 lesions). The extent of me-
tastases on PSMA ligand PET/CT was classified following the
PROMISE Classification [18] with modifications: low tumor
burden (≤ 3 metastases), intermediate tumor burden (> 3 but <
10 metastases), high tumor burden (≥ 10 metastases), and dif-
fuse bone marrow involvement.
Statistical analysis
Statistical analyses were performed using SPSS software ver.
26.0 (IBM,Armonk, NY, USA). Descriptive data are presented
as mean ± standard deviation and range. Survival data are ana-
lyzed by Kaplan-Meier curves and log-rank comparison.
Univariate cox regression for continuous variables was applied.
Multivariable analysis was undertaken for stratification of
probable prognostic markers. OS was calculated starting with
the first cycle of RLT and is presented as median ± standard
error and 95% confidence interval [CI]. For statistical compar-
ison between subgroups, an unpaired t test was performed. A p
value less than 0.05 was considered statistically significant.
Results
Patients’ characteristics
Fifty-four patients (Würzburg: n = 26; Freiburg: n = 28) who
underwent dual tracer PET/CT before at least one cycle of
PSMA-targeted RLT were included in this analysis. Detailed
characteristics of all included patients are given in Table 1.
Mean patient age was 71.4 ± 8.5 years (range: 52–90). Mean
time interval since initial diagnosis of prostate cancer and
imaging was 7.7 ± 5.6 years (range: 1.7–26.3) and median
initial Gleason score was 8 (range: 5–10, n = 48; unknown
in six patients). Performance status according to Eastern
Cooperative Oncology Group (ECOG) ranged from 0 to 3
(0: 52%; 1: 37%; 2: 9%; 3: 2%). Almost all patients (n = 52,
96%) presented with bone metastases. Other frequent sites of
metastatic spread included lymph nodes (n = 33, 61%), the
liver (n = 13, 24%), and the lungs (n = 8, 15%). At least one
visceral metastasis (liver, lung, kidney, adrenal gland, testis,
tumor in the (retro-) peritoneum, pleura, or leptomeningeal
carcinomatosis) was found in 23 patients (53%). A low or
intermediate tumor burden was found in two patients (4%)
each. The majority (n = 41; 76%) of patients presented with
a high tumor burden. Nine patients showed a diffuse bone
marrow involvement (16%). More than two thirds of patients
(69%) had been previously treated with at least one line of
chemotherapy (docetaxel: n = 37; cabazitaxel: n = 12). Two
patients had already undergone two cycles of RLT prior to
the current staging more than 1 year before. The median num-
ber of systemic treatment lines before RLT was 3.5 (range: 2–
6). Serum PSA level was 450 ± 916 ng/ml (range: 0.07–5000)
at first cycle of RLT. In total, 139 cycles of RLT were admin-
istered with a mean activity of 5.9 ± 0.6 GBq (range: 1.9–6.4).
Disease group classification
Discordant lesions were found in 18 patients. FDG+/PSMA−
lesions were seen mostly in the skeleton (n = 8) and the liver
Fig. 1 Corresponding axial slices of [18F]PSMA-1007 PET (first
column), FDG PET (second column), and CT (third column). a 72-
year-old patient with FDG+/PSMA- right hilar lymph node metastasis
(black arrow; histologically proven metastasis from prostate cancer). b
65-year old patient with concordant FDG+/PSMA+ bone metastases.
Fixed inverse gray-scale are displayed with SUV window setting from
0 to 10 ([18F]PSMA-1007 PET) and 0 to 5 (FDG PET), respectively
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(n = 8), two patients showed discordant uptake in lymph nodes,
one patient had a discordant prostate lesion, and a one patient
had discordant peritoneal tumor in the pelvis. It is possible that
patients had more than one “organ system” affected (e.g., bone
and liver metastases in one patient as well as bone metastases,
liver metastases, and a peritoneal tumor in the pelvis in another
patient). In 7 patients, only one FDG+/PSMA− lesion was
found, 8 patients had ≤ 3 discordant lesions, and in 3 patients,
≥ 4 FDG+/PSMA− lesions were detected. Patients with discor-
dant lesions had a high tumor burden on PSMA ligand PET/CT
(n = 15, 83%), and three patients even had a diffuse bone mar-
row involvement (17%).
Regarding the characteristics of the 18 subjects with one or
more FDG+/PSMA− lesions (Table 1), these patients received
significantly fewer cycles of RLT (2.0 ± 0.9, range: 1–4) than
the other patients (2.9 ± 1.1, range: 1–4; p = 0.005). No differ-
ence was found for median Gleason score (8 for both sub-
groups). In addition, serum PSA levels (543 ± 1258, range:
0.07–5000 ng/ml vs. 404 ± 608, range: 5–2650 ng/ml; p =
0.608), time since diagnosis of prostate cancer (6.3 ± 3, range:
1.8–11.6 years vs. 8.4 ± 6.6, range 1.7–26.3 years, p = 0.209),
pre-treatment with docetaxel (72.2% vs. 66.7%; p = 0.685),
and ECOG performance status (range: 0–3 vs. 0–2; p = 0.2)
did not differ significantly between subgroups.
Table 1 Patient characteristics of








Age (years) 71.4 (52–90) 70.4 (58–82) 71.9 (52–90)
Time since diagnosis of prostate cancer (years) 7.7 (1.7–26.3) 6.3 (1.8–11.6) 8.4 (1.7–26.3)
Gleason score 8 (5–10)* 8 (7–10)~ 8 (5–10)#
PSA (ng/ml) 450 (0.07–5000) 543 (0.07–5000) 404 (5–2650)
ECOG 0–3 0–3 0–2
Sites of disease: n (patients) n (patients) n (patients)
Prostate/local 16 4 12
Lymph node 33 12 21
Bone 52 18 34
Liver 13 9 4
Lung 8 4 4
Other 9 5 4
Previous treatment: n (patients) n (patients) n (patients)
Prostatectomy 28 9 19
Radiotherapy to prostate/ prostate bed 31 13 18
ADT 54 18 36
Abiraterone 44 15 29
Enzalutamide 29 9 20
Docetaxel 37 13 24
Cabazitaxel 12 3 9
[223Ra]Dichloride 8 3 5
Selective internal radiation therapy 2 0 2
PSMA RLT 2 1 1
Prostvac 1 1 0
Estramustin 1 0 1
Median lines of treatment before RLT 3.5 (2–6) 3.5 (2–6) 3.5 (2–6)
Number of RLT cycles n (patients) n (patients) n (patients)
1 cycle 54 18 36
2 cycles 44 12 32
3 cycles 26 5 21
4 cycles 15 1 14
PSA prostate specific antigen, ECOG performance status according to Eastern Cooperative Oncology Group,
ADT androgen deprivation therapy, PSMA RLT prostate-specific membrane antigen-targeted radioligand therapy,
other sites of disease: kidney, adrenal gland, testis, tumor in the (retro-) peritoneum, pleura, leptomeningeal
carcinomatosis; unknown in *n = 6, ~ n = 1, # n = 5
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Prognostic factors
Median OS of all patients (n = 54) was 11 ± 1.8 months (95%
CI 7.4–14.6 months). Patients with one or more FDG+/PSMA
− lesions (n = 18/54) had a significantly shorter OS (6.0 ±
0.5 months; 95% CI 5.0–7.0 months) than the other patients
(n = 36/54; OS: 16.0 ± 2.4months; 95%CI 11.2–20.8months;
p < 0.001; Fig. 2).
A significant difference in OS was also recorded between
patients with (n = 23/54; 7.0 ± 2.7 months, 95% CI 1.6–
12.4 months) and without visceral metastases (n = 31/54;
12.0 ± 2.1 months, 95% CI 7.9–16.1 months; p = 0.045) as
well as between patients with liver metastases (n = 13/54;
3.0 ± 1.1 months, 95% CI 0.9–5.1 months) and without liver
metastases (n = 41/54; 13.0 ± 2.2 months, 95% CI 8.7–
17.3 months; p < 0.001). On univariate cox regression, the
ECOG performance status (hazard ratio [HR]: 2.9 95% CI
1.7–5.0; p < 0.001) and the extent of metastases on PSMA
ligand PET/CT (HR 2.3 95%CI 1.1.–4.8; p = 0.024) were also
significant predictors of OS. Other factors (pretreatment with
docetaxel or cabazitaxel, patient’s age, lines of pretreatment,
time since initial diagnosis, and Gleason score) were not prog-
nostic for OS (p > 0.1, respectively).
On multivariable analysis between FDG+/PSMA− lesions,
visceral metastases, liver metastases, extent of metastases on
PSMA ligand PET/CT, ECOG, pretreatment with docetaxel
or cabazitaxel, patient’s age, lines of pretreatment, time since
initial diagnosis, and Gleason score, FDG+/PSMA− lesions
retained their prognostic capability regarding survival (HR 4.9
95% CI 1.7–14.3, p = 0.04) after stratification. Furthermore,
ECOG performance status (HR 4.5 95% CI 1.8–11.6, p =
0.02) and the presence of liver metastases (HR 7.6 95% CI
1.2–49.3, p = 0.034) were also significant prognostic markers
for OS. The other parameters were not prognostic for OS
(p > 0.1).
Discussion
Our analysis showed that FDG+/PSMA− lesions occurred in
one third (33%) of patients with mCRPC prior to RLT, which
is in line with a recent study by Wang et al. (33%) [19], and
slightly higher compared to the results of Hofmann et al.
(19%) [14]. FDG+/PSMA− lesions were found in skeleton
or liver in 44% of cases, which was comparable to prior results
in the study of Thang et al. (50% or 38%, respectively) [16].
Patients with FDG+/PSMA− lesions underwent significantly
fewer cycles of RLT as these patients presented more often
with a progression of disease under treatment. This could ei-
ther be due to a missing response to PSMA RLT, or the con-
sequence of a more aggressive disease. Presence of FDG+/
PSMA− lesions could be confirmed as a negative prognostic
factor: median OS for patients without discrepant FDG+/
PSMA− lesions was significantly longer with 16 ± 2.4 months
as compared to patients with FDG+/PSMA− lesions (6.0 ±
0.5 months). This finding is in line with the extended cohort
of the LuPSMA Trial with an OS of 13.3 months [15].
Whereas patients with PSMA-negative viable diseases per-
formed particularly poor, our results may indicate that RLT
prolongs survival in these patients as compared to subjects
being treated with best standard of care. In contrast to our
approach in which patients with PSMA-negative metastases
were offered PSMA-targeted RLT if this was their last thera-
peutic option and if the majority of metastases was PSMA-
Fig. 2 Kaplan-Meier curves of
median overall survival (OS) of
patients with FDG+/PSMA- le-
sions. These patients (n = 18, red
line) had an OS of 6.0 ±
0.5 months (95% CI 5.0–
7.0 months), whereas the other
patients (n = 36, blue line)
showed an OS of 16.0 ±
2.4 months (95% CI 11.2–
20.8 months; p < 0.001)
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positive, the LuPSMA trial excluded subjects due to low-
PSMA expression (8 of 16 patients) or FDG+/PSMA− find-
ings (8 of 16 patients) [14, 15]. In this cohort, patients with
FDG+/PSMA− lesions showed a poor median OS of only
3.9 months under standard of care, which is distinctly shorter
than the comparable cohort in our studywith 6.0 ± 0.5months.
Furthermore, the authors of the LuPSMA trial discuss that
RLT might have improved survival also in this subcohort
[16]. To our knowledge, this is the first analysis of patients
with dual tracer imaging undergoing RLT without exclusion
of patients with heterogeneous tumor lesions. Interestingly,
the majority of patients with discordant sites of disease (15/
18, 83%) had ≤ 3 FDG+/PSMA− lesions, though the impact
of these single lesions was already distinct on OS as shown in
a multivariable analysis also considering the extent of metas-
tases on PSMA ligand PET/CT.
As further negative prognostic factors, poorer ECOG status
and presence of liver metastases were confirmed on multivar-
iable analysis. This is in line with previous findings demon-
strating that the presence of visceral metastases, especially
liver metastases, results in poorer survival [20] [21]. ECOG
status has also been identified as a prognosticator of OS before
[22]. The extent of metastases on PSMA ligand PET/CT was
only a significant prognostic marker on univariate analysis.
Limitations
This retrospective study suffers from some limitations, the
first being the inclusion of a rather small, heterogeneous pa-
tient cohort. Second, PET/CT examinations were gained from
both [68Ga] and [18F]-labeled PSMA ligands, as both hospitals
adapted the radiolabeling procedure during the study period.
In order to address potential differences of the PSMA-ligands,
a robust visual categorization system with a substantial
interrater agreement was developed. Similarly, the impact of
different PET/CT scanners used at the two institutions seems
negligible. Additionally, the influence of previous cytotoxic
treatments can be considered rather small, as these treatments
were stopped several weeks before PSMA ligand PET/CT and
disease progression was documented.
Finally, the high physiological tracer uptake of the liver
when using [18F]PSMA-1007 is a frequent and inherent lim-
itation with possible false-negative hepatic lesions [23].
Conclusion
This study demonstrates a significantly poorer response to
PSMA-directed RLT in patients with mCRPC and FDG+/
PSMA− lesions, which occurs in about one third of patients.
These discordant findings probably indicate a more aggressive
biology of disease, and it remains to be elucidated if this patient
population still benefits fromRLT. Therefore, prospective trials
investigating optimal treatment protocols for patients with
FDG+/PSMA− lesions, e.g. combination of PSMA-directed
RLT and cytotoxic drugs or immunotherapy, are highly
warranted.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s00259-020-05160-8.
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